EGFR and cancer: Based on the simulation data, we propose a top 15 list of anti-miRNAs (p<0.05) with most significant impact on the EGFR signaling pathway (Table 2), and suggest that those anti-miRNAs could be potential test candidates for follow-up studies assessing the impact of distinct miRNA inhibitors on EGFR pathway activation in cancer derived cell lines or other suitable model systems.